Building something great: UK's Global Bioscience Cluster 2016

Read also

• To infinity and beyond: how far can mRNA vaccine technology go?

  With over 63 million confirmed cases and over 1.4 million deaths worldwide as of the start of December, the COVID-19 pandemic has certainly lit a fire under the pharmaceutical industry in the pursuit of therapeutics. In the process, with the recent emergency use authorisation in the UK for Pfizer and BioNTech’s BNT-162b2 vaccine, and the 94.5% efficacy reported by Moderna for its mRNA-1273 vaccine, a new technology has shot to the forefront: the mRNA vaccine.

  Topics Diseases Drug Development Landscape Vaccines

  Read Blog

• Find the right investigators and sites for your clinical trial using granular, real-world data.

  27 Nov 2020

  Gain vital insight into study feasibility, site selection, and investigator prioritization with granular data from the new Informa Pharma Intelligence Patient Proximity API. Protect yourself against costly trial delays by using it to choose the right investigators with relevant and sizable patient proximity. 

  Topics Clinical Trial Optimization Clinical Trials

  Full Video

• Biomedtracker: see the drug development process through anal...

  COVID-19 Infographic

  Access the infographic below which explores the number of treatment drugs for COVID-19 currently in clinical trials or in development, events including progress updates, partnerships, regulatory and trial announcements etc, and the number of articles published on COVID-19 as of March 3, 2020. This data has been tracked and reported via Informa Pharma Intelligence’s clinical, regulatory and commercial data and analytics, and news and insight tools including Biomedtracker, Trialtrove, Pharmaprojects, Scrip, Pink Sheet, Medtech Insight, and Generics Bulletin etc.

  Topics Coronavirus

  View Infographic

• Pharma RD Annual Review 2020 Whitepaper

  By Ian Lloyd

  Using the new, granular datapoints in Pharmaprojects, Senior Director Ian Lloyd presents his expert insights into pharma’s R&D activities over the past year and what they may mean for the pipeline during the year to come. The 27th instalment of the Annual Review, this version takes advantage of improvements to Pharmaprojects’ data granularity to bring you details on pharma R&D trends

  Topics Drug Development Landscape Drug Review Research & Development

  View White Paper

• New Active Substances (NAS) Launched During 2019 Infographic

  By Ian Lloyd

  Don’t miss your view into the NAS that made an impact last year, your follow-up to the Pharma R&D Annual Review 2020 webinar.

  Topics Clinical Trials Research & Development

  View Infographic

• Pharma R&D Annual Review 2020 Whitepaper - NAS Supplement

  By Ian Lloyd

  Recently, Pharma Intelligence brought you the Pharma R&D Annual Review 2020 Webinar, followed up with the NAS (New Active Substances) Infographic. We now invite you to go even deeper into pharma R&D successes for 2019 with your free copy of the NAS Supplement. 

  Topics Clinical Trials Research & Development

  View White Paper